Skip to main content
Hit enter to search or ESC to close
Close Search
RIGImmune Inc.
Menu
  • About Us
    • The Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Technology
  • Partnership and Collaborations
  • Contact Us
  • News

News

2022 – RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments

2022 – RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital

Publications

2021 – The molecular mechanism of RIG-I activation and signaling

2021 – A stem-loop RNA RIG-I agonist confers prophylactic and therapeutic protection against acute and chronic SARS-CoV-2 infection in mice

2019 – Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses

2014 – Parts, assembly and operation of the RIG-I family of motors

2014 – Hepatic RIG-I Predicts Survival and Interferon-α Therapeutic Response in Hepatocellular Carcinoma

2013 – Defining the functional determinants for RNA surveillance by RIG-I

2011 – Structural Insights into RNA Recognition by RIG-I

2002 – mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties

© 2022 RIGImmune Inc. | Dallas Web Designs

Close Menu
  • About Us
    • The Company
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Technology
  • Partnership and Collaborations
  • Contact Us
  • News

© 2022 RIGImmune Inc.